Piper Sandler Initiates Coverage On Context Therapeutics with Overweight Rating, Announces Price Target of $4.5
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has initiated coverage on Context Therapeutics (NASDAQ:CNTX) with an Overweight rating and a price target of $4.5.
May 16, 2024 | 9:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has initiated coverage on Context Therapeutics with an Overweight rating and a price target of $4.5, indicating a positive outlook for the stock.
The initiation of coverage with an Overweight rating and a specific price target of $4.5 by a reputable analyst from Piper Sandler is likely to boost investor confidence and positively impact the stock price of Context Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100